Drug design - Chemistry and biology

BioTechniques

Volumn 31, Issue 5, 2001, Pages 1164-1171

  Sawyer, T K ^a  

^a ARIAD PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; BLOOD CLOTTING FACTOR 10A INHIBITOR; CATHEPSIN K; CYCLIN DEPENDENT KINASE INHIBITOR; CYSTEINE PROTEINASE INHIBITOR; ENDOTHELIAL CELL GROWTH FACTOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; ONCOPROTEIN; PHOSPHOLIPASE A2 INHIBITOR; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN BCL 2; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; PROTEINASE INHIBITOR; RENIN INHIBITOR; SIALIDASE INHIBITOR; STAT PROTEIN; THROMBIN INHIBITOR;

BIOLOGY; CHEMISTRY; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; MOLECULAR RECOGNITION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0035173655     PISSN: 07366205     EISSN: None     Source Type: Journal    
DOI: 10.2144/01315dd01     Document Type: Review

References (79)

1. High-throughput docking for lead generation
2. Integration of combinatorial chemistry and structure-based drug design
3. Bcx-1812 (rwj-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuramidinase inhibitor through structure-based drug design
4. The impact of genomics on drug discovery
5. Modern computational chemistry and drug discovery: Structure-generating programs
6. Grow-Mol, a de novo computer program, and its application to thermolysis and pepsin: Results of the design and synthesis of a novel inhibitor
7. Structure-based library design: Molecular modeling merges with combinatorial chemistry
8. Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules, design, structure-activity relationships and X-ray crystal structures
9. Adensoine analogues as selective inhibitors of glyceraldehyde-3-phosphate dehydrogenase of trypanosomatidae via structure-based drug design
10. Chemogenomic approaches in drug discovery
11. The crystal structures of human thrombin complexed with active site-directed diamino benzo[b]thiophene derivatives: A binding mode for a structural novel class of inhibitors
12. Structure of an extracellular gp130 cytokine receptor signaling complex
13. Pharmaceutical applications of NMR
14. Signal transduction drug discovery: Targets, mechanisms, and structure-based design
15. Generating consistent sets of thermodynamic and structural data for analysis of protein-ligand interactions
16. Inhibitor binding to active and inactive CDK2: The crystal structure of CDK2-cyclin A/indirubin-5-sulphonate
17. Applications of NMR in drug discovery
18. Structure-based design of potent CDK1 inhibitors derived from olomoucine
19. Recent developments in rational structure-based drug design
20. Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents
21. Lead compounds discovered from libraries
22. High-throughput X-ray crystallography for structure-based drug design
23. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors
24. Designing small-molecule switches for protein-protein interactions
25. Peptide-binding G protein-coupled receptors: New opportunities for drug design
26. Allosteric activation of a spring-loaded natriuretic peptide receptor dimer by hormone
27. T cell receptor MHC interactions up close
28. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: Insights into the mechanisms of drug resistance
29. Bcl-2 family proteins as targets for anticancer drug design
30. STAT proteins: Novel molecular targets for cancer drug discovery
31. Discovery of novel aldose reductase inhibitors using a protein structure-based approach: 3D database search followed by design and synthesis
32. Computational approaches to structure-based drug design
33. A novel serine protease inhibition motif involving a multicentered short hydrogen bonding network at the active site
34. Structure-based inhibitor design for CDK2 a cell cycle controlling protein kinase
35. Recent developments in structure-based drug design
36. Virtual screening: An effective tool for lead structure discovery
37. Crystal structure of the ectodomain of human transferrin receptor
38. Chemical ligands, genomics and drug discovery
39. Bioinformatics and computational chemistry in molecular design: Recent advances and their applications
40. The use of 3D structural data in the design of specific factor Xa inhibitors
41. Recent developments in computational proteomics
42. Cyclic ketone inhibitors of the cysteine protease cathepsin K
43. Diverse viewpoints on computational aspects of molecular diversity
44. 3-D pharmacophores in drug discovery
45. Structure-based design of a new class of anti-inflammatory drugs: Secretory phospholipase A2 inhibitors
46. Structural genomics: Opportunities and challenges
47. A general and fast scoring function for protein-ligand interactions: A simplified potential approach
48. Towards 3D structures of G protein-coupled receptors: A multidisciplinary approach
49. Structure-based drug design
50. Structure-based discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding site
51. Discovering novel ligands for macromolecules using X-ray crystallographic screening
52. Protein models in drug discovery
53. Cheminformatics: A tool for decision-makers in drug discovery
54. Crystal structure of rhodopsin: A G protein-coupled receptor
55. Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD17890: A lead HIV protease inhibitor
56. Structure-based drug design: The discovery of novel nonpeptide orally active inhibitors of human renin
57. Substituted benzamide inhibitors of human rhinovirus 3C protease: Structure-based design, synthesis and biological evaluation
58. The crystal structure of a T cell receptor in complex with peptide and MHC class II
59. Applications of NMR in drug discovery
60. Ligand-protein database: Linking protein-ligand complex structures to binding data
61. Drug discovery in 3-D
62. Src inhibitors: Genomics to therapeutics
63. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase
64. Industrializing structural biology
65. Structure-based design of an osteoclast-selective, nonpeptide Src homology-2 inhibitor with in vivo antiresorptive activity
66. Structure of complement receptor 2 in complex with its C3d ligand
67. The structure-based design of ATP-site directed protein kinase inhibitors
68. A structurally biased combinatorial approach for discovering anti-picornaviral compounds
69. Glossary of terms used in computational drug design
70. Property-based design: Optimization of drug absorption and pharmacokinetics
71. The new partnership of genomics and chemistry for accelerated drug discovery
72. Towards understanding the mechanisms of molecular recognition by computer simulations of ligand protein interactions
73. Putting two and two together: Crystal structure of te FGF-receptor complex
74. Inhibitors of HIV-1 protease: A major success of structure-based drug design
75. 3
76. Crystal structures of c-Src reveal features of its autoinhibitory mechanism
77. Protein tyrosine phosphatases: Prospects for therapeutics
78. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors